Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aim: To assess the extent, safety, efficacy and tolerability of reported off‐licence exenatide use through a nationwide audit. Methods: The Association of British Clinical Diabetologists hosted a password‐protected, online collection of anonymized data of exenatide use in real clinical practice. Three hundred and fifteen contributors from 126 centres across UK provided data on 6717 patients. HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non‐insulin and insulin‐treated patients. Results: Four thousand eight hundred and fifty‐seven patients had baseline and follow‐up treatment status with mean (±s.d.) baseline HbA1c 9.45 ± 1.69% and BMI 40.0 ± 8.2 kg/m 2 . Of the 4857 patients, 1921 (39.6%) used exenatide with insulin. Comparing patients who continued insulin with exenatide with non‐insulin‐treated patients, mean (±s.e.) latest HbA1c and weight reduction (median 26 weeks) were 0.51 ± 0.06 versus 0.94 ± 0.04% (p < 0.001) and 5.8 ± 0.2 versus 5.5 ± 0.1 kg (p = 0.278). Insulin‐treated patients had higher rates of exenatide discontinuation (31.0 vs. 13.9%, p < 0.001), hypoglycaemia (8.9 vs. 6.1%, p < 0.001), gastrointestinal side effects (28.4 vs. 25.0%, p = 0.008) and treatment dissatisfaction (20.8 vs. 5.7%, p < 0.001). However, 34.2% of the patients continuing insulin still achieved HbA1c reduction ≥1%. There was significant insulin discontinuation, dose reduction and greater sulphonylurea discontinuation among insulin‐treated patients. Conclusions: Addition of exenatide to obese, insulin‐treated patients can improve glycaemia and weight. Adverse events were statistically but probably not clinically significantly higher, but combination treatment was less well tolerated. Overall, exenatide was less effective in lowering HbA1c among insulin‐treated patients, although significant number of insulin‐treated patients still achieved significant HbA1c, weight and insulin reductions. Further research into identifying obese, insulin‐treated patients who will tolerate and benefit from exenatide treatment is urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Overall, rates of hypoglycaemia were low and comparable to other retrospective studies of exenatide and insulin [18,19] but lower in comparison with trials utilizing concurrent sulphonylurea therapy [2,3] and the recent randomized trial by Buse et al.”
ResultHeine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 1×
“5%, respectively, as compared with placebo [20,21].”
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Khunti, K., Nikolajsen, A., Thorsted, B. L., Andersen, M., Davies, M. J., & Paul, S. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12626 · Cited by 256
Glucagon-like peptide-1 analogues: An overview
Gupta, V. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111625 · Cited by 186
“[54] Most of the studies employing GLP‑1 analogues have selected patients with a high body mass index (BMI) and have also demonstrated significant weight reduction.”
BackgroundGLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Dhesi, B., Chauhan, H., & Basu, A. (2013) · Practical Diabetes · doi:10.1002/pdi.1767 · Cited by 4
Metadata
- Authors
- Thong, K. Y., Jose, B., Sukumar, N., Cull, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., & contributors, O. B. O. T. A. N. E. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-06-21
- Volume
- 13
- Issue
- 8
- Pages
- 703-710
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2166714657
- Cited by
- 96
- References
- 6
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01393.x
- The paper
- Thong, K. Y., Jose, B., Sukumar, N., Cull, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., & contributors, O. B. O. T. A. N. E. A. (2011). Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01393.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.